Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Contract revenue	$ 1,028	$ 0
Operating expenses
Research and development	26,682	39,624
General and administrative	23,946	26,475
Impairment loss	3,714	0
Total operating expenses	54,342	66,099
Loss from operations	(53,314)	(66,099)
Other income (expense), net
Interest income and other, net	1,763	3,301
Interest expense and other, net	(5,033)	(5,085)
Net loss	(56,584)	(67,883)
Net loss attributable to non-controlling interest	(26,566)	(33,913)
Net loss attributable to Rani Therapeutics Holdings, Inc.	$ (30,018)	$ (33,970)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-basic	$ (1.05)	$ (1.33)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-diluted	$ (1.05)	$ (1.33)
Weighted average Class A common share outstanding-basic	28,476	25,505
Weighted average Class A common share outstanding-diluted	28,476	25,505